tiprankstipranks
Insmed (CH:IM8N)
NASDAQ:IM8N
Switzerland Market
IM8N
Insmed
RESEARCH TOOLSreports

Insmed (IM8N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

IM8N Analyst Ratings

Strong Buy
19Ratings
Strong Buy
19 Buy
0 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Insmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IM8N Stock 12 Month Forecast

Average Price Target

$161.59
Based on 19 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $161.59 with a high forecast of $196.44 and a low forecast of $129.34. The average price target represents a ― change from the last price of ―.
eyJuYXZpZ2F0b3IiOnsiZGlzYWJsZWQiOnRydWV9LCJleHBvcnRpbmciOnsiZW5hYmxlZCI6ZmFsc2V9LCJ0aXRsZSI6eyJ0ZXh0IjpudWxsfSwiY2hhcnQiOnsiaGVpZ2h0IjoyMDAsInN0eWxlIjp7ImZvbnRGYW1pbHkiOiJSb2JvdG8gRmxleCwgLWFwcGxlLXN5c3RlbSwgQmxpbmtNYWNTeXN0ZW1Gb250LCBTZWdvZSBVSSwgUm9ib3RvLCBIZWx2ZXRpY2EsIEFyaWFsLCBzYW5zLXNlcmlmLCBBcHBsZSBDb2xvciBFbW9qaSwgU2Vnb2UgVUkgRW1vamksIFNlZ29lIFVJIFN5bWJvbCIsImZvbnRXZWlnaHQiOiI0MDAiLCJjb2xvciI6IiM1ZDVkNWUifX0sInlBeGlzIjp7ImxhYmVscyI6eyJzdHlsZSI6eyJjb2xvciI6ImluaGVyaXQifX0sInZpc2libGUiOmZhbHNlfSwicGxvdE9wdGlvbnMiOnsic2VyaWVzIjp7InN0YXRlcyI6eyJpbmFjdGl2ZSI6eyJvcGFjaXR5IjoxfX19fSwieEF4aXMiOnsibGFiZWxzIjp7InN0eWxlIjp7ImNvbG9yIjoiaW5oZXJpdCJ9fSwidmlzaWJsZSI6ZmFsc2V9LCJsZWdlbmQiOnsic3ltYm9sUmFkaXVzIjowLCJzeW1ib2xQYWRkaW5nIjo0LCJzeW1ib2xIZWlnaHQiOjE0LCJib3JkZXJXaWR0aCI6MCwic3ltYm9sV2lkdGgiOjE0LCJhbGlnbiI6ImxlZnQiLCJ2ZXJ0aWNhbEFsaWduIjoiYm90dG9tIiwiZW5hYmxlZCI6ZmFsc2V9LCJ0b29sdGlwIjp7ImJhY2tncm91bmRDb2xvciI6IndoaXRlIn0sImNyZWRpdHMiOnsiZW5hYmxlZCI6ZmFsc2V9LCJhY2Nlc3NpYmlsaXR5Ijp7ImRlc2NyaXB0aW9uIjoiIn0sInNlcmllcyI6W3sidHlwZSI6ImFyZWEiLCJkYXRhIjpbXX1dfQ==
Highest Price Target$196.44Average Price Target$161.59Lowest Price Target$129.34
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CH:IM8N
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF149.55→CHF141.47
Buy
―
Reiterated
06/23/26
Jefferies Reaffirms Their Buy Rating on Insmed (INSM)
TD Cowen Analyst forecast on CH:IM8N
Ritu Baral
TD Cowen
TD Cowen
CHF196.44
Buy
―
Reiterated
06/16/26
Ritu Baral Reiterates Buy on Insmed, Maintains $243 Price Target Amid Strong Respiratory Franchise Momentum and Improving Profitability Outlook
Mizuho Securities Analyst forecast on CH:IM8N
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
CHF163.29→CHF155.21
Buy
―
Reiterated
06/15/26
Mizuho cuts Insmed target, sees buying opportunity after selloffMizuho cuts Insmed target, sees buying opportunity after selloff
Bank of America Securities Analyst forecast on CH:IM8N
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF172.99
Buy
―
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on CH:IM8N
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
CHF189.97
Buy
―
Reiterated
06/10/26
Analysts' Top Healthcare Picks: Insmed (INSM), Harrow Health (HROW)
J.P. Morgan Analyst forecast on CH:IM8N
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF145.51→CHF144.7
Buy
―
Assigned
06/08/26
Insmed price target lowered to $179 from $180 at JPMorganInsmed price target lowered to $179 from $180 at JPMorgan
Roth MKM Analyst forecast on CH:IM8N
Adam Walsh
Roth MKM
Roth MKM
CHF171.38
Buy
―
Reiterated
06/08/26
Insmed stock price decline a 'buying opportunity', says Roth CapitalInsmed stock price decline a 'buying opportunity', says Roth Capital
RBC Capital Analyst forecast on CH:IM8N
Leonid Timashev
RBC Capital
RBC Capital
CHF165.72→CHF157.63
Buy
―
Reiterated
06/05/26
Price target revised to $195 from $205 based on our KOL feedback.
Wells Fargo Analyst forecast on CH:IM8N
Benjamin Burnett
Wells Fargo
Wells Fargo
CHF129.34
Buy
―
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), HCA Healthcare (NYSE: HCA) and Insmed (NASDAQ: INSM)
UBS Analyst forecast on CH:IM8N
Ashwani Verma
UBS
UBS
CHF134.19
Buy
―
Reiterated
06/03/26
UBS Sticks to Their Buy Rating for Insmed (INSM)
Barclays Analyst forecast on CH:IM8N
Eliana Merle
Barclays
Barclays
CHF191.59
Buy
―
Reiterated
05/28/26
Barclays Remains a Buy on Insmed (INSM)
Truist Financial Analyst forecast on CH:IM8N
Danielle Brill
Truist Financial
Truist Financial
CHF149.55
Buy
―
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Astrana Health (NASDAQ: ASTH) and Baxter International (NYSE: BAX)
William Blair Analyst forecast on CH:IM8N
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/18/26
Analyst Reaffirms Buy on Insmed, Citing Strong ENCORE Phase IIIb Arikayce Data and TPIP IPF Upside
Evercore ISI Analyst forecast on CH:IM8N
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
CHF168.14→CHF130.96
Buy
―
Reiterated
05/15/26
Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)
H.C. Wainwright Analyst forecast on CH:IM8N
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF177.84
Buy
―
Reiterated
05/08/26
Insmed earnings selloff a buying opportunity, says H.C. WainwrightInsmed earnings selloff a buying opportunity, says H.C. Wainwright
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CH:IM8N
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF149.55→CHF141.47
Buy
―
Reiterated
06/23/26
Jefferies Reaffirms Their Buy Rating on Insmed (INSM)
TD Cowen Analyst forecast on CH:IM8N
Ritu Baral
TD Cowen
TD Cowen
CHF196.44
Buy
―
Reiterated
06/16/26
Ritu Baral Reiterates Buy on Insmed, Maintains $243 Price Target Amid Strong Respiratory Franchise Momentum and Improving Profitability Outlook
Mizuho Securities Analyst forecast on CH:IM8N
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
CHF163.29→CHF155.21
Buy
―
Reiterated
06/15/26
Mizuho cuts Insmed target, sees buying opportunity after selloffMizuho cuts Insmed target, sees buying opportunity after selloff
Bank of America Securities Analyst forecast on CH:IM8N
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF172.99
Buy
―
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on CH:IM8N
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
CHF189.97
Buy
―
Reiterated
06/10/26
Analysts' Top Healthcare Picks: Insmed (INSM), Harrow Health (HROW)
J.P. Morgan Analyst forecast on CH:IM8N
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF145.51→CHF144.7
Buy
―
Assigned
06/08/26
Insmed price target lowered to $179 from $180 at JPMorganInsmed price target lowered to $179 from $180 at JPMorgan
Roth MKM Analyst forecast on CH:IM8N
Adam Walsh
Roth MKM
Roth MKM
CHF171.38
Buy
―
Reiterated
06/08/26
Insmed stock price decline a 'buying opportunity', says Roth CapitalInsmed stock price decline a 'buying opportunity', says Roth Capital
RBC Capital Analyst forecast on CH:IM8N
Leonid Timashev
RBC Capital
RBC Capital
CHF165.72→CHF157.63
Buy
―
Reiterated
06/05/26
Price target revised to $195 from $205 based on our KOL feedback.
Wells Fargo Analyst forecast on CH:IM8N
Benjamin Burnett
Wells Fargo
Wells Fargo
CHF129.34
Buy
―
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), HCA Healthcare (NYSE: HCA) and Insmed (NASDAQ: INSM)
UBS Analyst forecast on CH:IM8N
Ashwani Verma
UBS
UBS
CHF134.19
Buy
―
Reiterated
06/03/26
UBS Sticks to Their Buy Rating for Insmed (INSM)
Barclays Analyst forecast on CH:IM8N
Eliana Merle
Barclays
Barclays
CHF191.59
Buy
―
Reiterated
05/28/26
Barclays Remains a Buy on Insmed (INSM)
Truist Financial Analyst forecast on CH:IM8N
Danielle Brill
Truist Financial
Truist Financial
CHF149.55
Buy
―
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Astrana Health (NASDAQ: ASTH) and Baxter International (NYSE: BAX)
William Blair Analyst forecast on CH:IM8N
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/18/26
Analyst Reaffirms Buy on Insmed, Citing Strong ENCORE Phase IIIb Arikayce Data and TPIP IPF Upside
Evercore ISI Analyst forecast on CH:IM8N
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
CHF168.14→CHF130.96
Buy
―
Reiterated
05/15/26
Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)
H.C. Wainwright Analyst forecast on CH:IM8N
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF177.84
Buy
―
Reiterated
05/08/26
Insmed earnings selloff a buying opportunity, says H.C. WainwrightInsmed earnings selloff a buying opportunity, says H.C. Wainwright
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months
Jessica FyeJ.P. Morgan
Success Rate
14/19 ratings generated profit
74%
Average Return
+23.08%
Copying Jessica Fye's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +23.08% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
18/20 ratings generated profit
90%
Average Return
+86.87%
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +86.87% per trade.
2 Years
Joseph SchwartzLeerink Partners
Success Rate
18/20 ratings generated profit
90%
Average Return
+170.81%
Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +170.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IM8N Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
2
6
8
25
32
Buy
49
40
45
30
19
Hold
5
5
2
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
56
51
55
56
51
In the current month, IM8N has received 51 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IM8N average Analyst price target in the past 3 months is 161.59.
Each month's total comprises the sum of three months' worth of ratings.

IM8N Financial Forecast

IM8N Earnings Forecast

Next quarter’s earnings estimate for IM8N is -$0.59 with a range of -$0.87 to -$0.25. The previous quarter’s EPS was -$0.60. IM8N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.
Next quarter’s earnings estimate for IM8N is -$0.59 with a range of -$0.87 to -$0.25. The previous quarter’s EPS was -$0.60. IM8N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.

IM8N Sales Forecast

Next quarter’s sales forecast for IM8N is $310.33M with a range of $297.01M to $329.24M. The previous quarter’s sales results were $243.11M. IM8N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.
Next quarter’s sales forecast for IM8N is $310.33M with a range of $297.01M to $329.24M. The previous quarter’s sales results were $243.11M. IM8N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.

IM8N Stock Forecast FAQ

What is CH:IM8N’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is 161.59.
    What is CH:IM8N’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:IM8N, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Insmed a Buy, Sell or Hold?
        Insmed has a consensus rating of Strong Buy, which is based on 19 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Insmed’s share price target?
          The average share price target for Insmed is 161.59. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $196.44 ,and the lowest forecast is $129.34. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Insmed?
            Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
              How can I buy shares of Insmed?
              To buy shares of CH:IM8N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.